Uzman DENİZ TURAL

Yayın Ağı

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler 40

1. Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

Kuzu O. F., BÖLEK H., Sertesen Camoz E., Karakas H., Sekmek S., Sim S., et al.

BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded)

2. Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

BÖLEK H., Kuzu O. F., Sertesen Camoz E., Sim S., Sekmek S., Karakas H., et al.

Clinical and Translational Oncology , cilt.27, sa.7, ss.3110-3120, 2025 (SCI-Expanded)

3. The impact of smoking on nivolumab outcomes in renal cell carcinoma: Real-world data from the Turkish Oncology Group Kidney Cancer Consortium

Sertesen Camoz E., BÖLEK H., Kuzu O. F., Sim S., Karakaş H., Sekmek S., et al.

Oncologist , cilt.30, sa.7, 2025 (SCI-Expanded)

4. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

BÖLEK H., Kuzu O. F., Sertesen Camoz E., Sim S., Sekmek S., Karakas H., et al.

Cancer Communications , cilt.45, sa.5, ss.572-576, 2025 (SCI-Expanded)

5. Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

BÖLEK H., Sertesen E., Kuzu O. F., Tural D., Sim S., Nahit Şendur M. A., et al.

Clinical Genitourinary Cancer , cilt.23, sa.1, 2025 (SCI-Expanded)

6. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

Sekmek S., BÖLEK H., Kuzu O. F., Camoz E. S., Sim S., Karakaş H., et al.

Immunotherapy , cilt.17, sa.9, ss.649-655, 2025 (SCI-Expanded)

7. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

Aykan M. B., BÖLEK H., YEKEDÜZ E., Sertesen E., Tural D., Karaçin C., et al.

Therapeutic Advances in Medical Oncology , cilt.17, 2025 (SCI-Expanded)

8. Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes

Ozbay M. F., Harputluoglu H., KARACA M., TEKİN Ö. F., Şendur M. A. N., Kaplan M. A., et al.

Cancers , cilt.16, sa.22, 2024 (SCI-Expanded)

9. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Kilickap S., Ozturk A., Karadurmus N., KORKMAZ T., Yumuk P. F., ÇİÇİN İ., et al.

Medicine , cilt.103, sa.21, 2024 (SCI-Expanded)

10. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.

LUNG CANCER , cilt.148, ss.48-54, 2020 (SCI-Expanded)

11. Hepatitis B and C rates are significantly increased in certain solid tumors: A large retrospective study

Kocoglu H., Karaca M., Tural D., Hocaoglu E., OKUTURLAR Y., Fetullahoglu Z., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.14, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

12. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy

ERYILMAZ M. K., Mutlu H., SALIM D. K., MUSRI F. Y., Tural D., Bassorgun I., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.22, sa.3, ss.533-536, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

13. Sorafenib-induced severe urticaria in a patient with hepatocellular cancer

Musri F. Y., Mutlu H., Salim D. K., Eryilmaz M. K., ÜNAL B., Tural D., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.22, sa.2, ss.350-353, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

14. Metronomic maintenance chemotherapy in patients presenting with paraneoplastic autoimmune hepatitis with recurrent thymic carcinoma

Salim D. K., Mutlu H., Eryilmaz M. K., Musri F. Y., Tural D., COŞKUN H. Ş.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.22, sa.2, ss.313-315, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

15. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer

Gunduz S., Mutlu H., Tural D., Yildiz O., Uysal M., COŞKUN H. Ş., et al.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , cilt.11, sa.4, ss.288-292, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

16. Is there any relation between PET-CT SUVmax value and prognostic factors in locally advanced breast cancer?

Tural D., Salim D. K., Mutlu H., ERKILIÇ M., GUNDUZ S., KARAKURT M., et al.

JOURNAL OF BUON , cilt.20, sa.5, ss.1282-1286, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

17. Late relapse of testicular cancer: Recurrence after 24 years and treatment with chemotherapy alone

Akar E., Tural D., Arslan D., BAŞSORGUN C. İ., Yildiz O.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.11, sa.3, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

18. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.

Arslan D., Tural D., Koca T., Taştekin D., Cerkeslı A. K., Basaran H., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.20, sa.2, ss.573-9, 2015 (SCI-Expanded)

19. Mortality in Colorectal Cancer and Use of Statins

Tural D., KILIÇKAP S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.33, sa.7, ss.810, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

20. First-Line Crizotinib in ALK-Positive Lung Cancer

Tural D., KILIÇKAP S.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.372, sa.8, ss.781, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

21. The Necessity of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma Using Antiangiogenic Targeted Therapy After Interferon Alfa-2b

Mutlu H., Gunduz S., Buyukcelik A., Yildiz O., Uysal M., Tural D., et al.

CLINICAL GENITOURINARY CANCER , cilt.12, sa.6, ss.447-450, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

22. Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer

Tural D., Selcukbiricik F., Yildiz O., Elcin O., ERDAMAR ÇETİN A. S., Guney S., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.19, sa.5, ss.889-896, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

23. P95 HER2 fragments and breast cancer outcome

Tural D., Akar E., Mutlu H., KILIÇKAP S.

EXPERT REVIEW OF ANTICANCER THERAPY , cilt.14, sa.9, ss.1089-1096, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

24. Mortality in Prostate Cancer and Use of Statins

Tural D., YÜCE D., KILIÇKAP S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.32, sa.21, ss.2274, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

25. Non-metastatic Ewing's sarcoma family of tumors of bone in adolescents and adults: prognostic factors and clinical outcome-single institution results

ÇOLPAN ÖKSÜZ D., Tural D., DİNÇBAŞ H. F., Dervisoglu S., TURNA Z. H., Hiz M., et al.

TUMORI , cilt.100, sa.4, ss.452-458, 2014 (SCI-Expanded)

26. The effect of autoimmunity on the development time of microvascular complications in patients with type 1 diabetes mellitus

ARSLAN D., TURAL D., TEMİZEL M., AKIN O., GÜNDÜZ S., TATLI A. M., et al.

MEDICAL SCIENCE MONITOR , cilt.20, ss.1176-1179, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

27. Pilomatrix carcinoma of the scalp with pulmonary metastasis: A case report of a complete response to oral endoxan and etoposide

Arslan D., Gündüz S., Avci F., Tatlı A. M., Uysal M., Tural D., et al.

ONCOLOGY LETTERS , cilt.7, sa.6, ss.1959-1961, 2014 (SCI-Expanded)

28. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

Tural D., BATUR Ş., ERDAMAR ÇETİN A. S., Akar E., KEPİL N., Mandel N. M., et al.

TUMOR BIOLOGY , cilt.35, sa.2, ss.1041-1049, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

29. PET-CT changes the management and improves outcome in patients with recurrent colorectal cancer

Tural D., Selcukbiricik F., SAĞER M. S., Akar E., Yildiz O., Serdengecti S.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.10, sa.1, ss.121-126, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

30. Molecular Types and Neoadjuvant Chemotherapy in Patients with Breast Cancer- While Molecular Shifting is More Common in Luminal a Tumors, The Pathologic Complete Response is Most Frequently Observed in Her-2 Like Tumors

Salim D. K., Mutlu H., Eryilmaz M. K., Musri F. Y., Tural D., GUNDUZ S., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.21, ss.9379-9383, 2014 (SCI-Expanded)

31. What is the optimal treatment in clinical stage T3N0M0 rectal cancer?

Tural D., Yildiz O., Elcin O., ERDAMAR ÇETİN A. S., Guney S., Demireli F., et al.

JOURNAL OF BUON , cilt.19, sa.1, ss.97-102, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

32. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system

Arslan D., BOZCUK H., Gündüz S., Tural D., TATTLI A. M., Uysal M., et al.

Asian Pacific Journal of Cancer Prevention , cilt.15, sa.6, ss.2465-2472, 2014 (SCI-Expanded)

33. Is Taxane-Cisplatin-Fluorouracil Superior to Cisplatin-Fluorouracil As Induction Chemotherapy in Outcome in Locally Advanced Head and Neck Cancers?

Tural D., Kilickap S.

JOURNAL OF CLINICAL ONCOLOGY , cilt.32, sa.3, ss.259, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

34. Cancer Pain Prevalence and its Management

Arslan D., Koca T., Akar E., Tural D., Ozdogan M.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.20, ss.8557-8562, 2014 (SCI-Expanded)

35. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy

Mutlu H., Arslan D., Gunduz S., Tural D., Buyukcelik A., CIHAN Y. B., et al.

CHEMOTHERAPY , cilt.60, sa.2, ss.107-111, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

36. The Neutrophil to Lymphocyte Ratio has a High Negative Predictive Value for Pathologic Complete Response in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Eryilmaz M. K., Mutlu H., Salim D. K., Musri F. Y., Tural D., COŞKUN H. Ş.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.18, ss.7737-7740, 2014 (SCI-Expanded)

37. Human papillomavirus is independent prognostic factor on outcome of oropharyngeal squamous cell carcinoma

Tural D., Elicin O., BATUR Ş., Arslan D., ÖZ A. B., Serdengecti S., et al.

TUMOR BIOLOGY , cilt.34, sa.6, ss.3363-3369, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

38. Herbal Administration and Interaction of Cancer Treatment

Arslan D., Tural D., Akar E.

JOURNAL OF PALLIATIVE MEDICINE , cilt.16, sa.11, ss.1466-1476, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

39. Gastric cancer: A case study in Turkey

Tural D., Selcukbiricik F., Akar E., Serdengecti S., Buyukunal E.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.9, sa.4, ss.644-648, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

40. Increase in the Rate of HPV Positive Oropharyngeal Cancers During 1996-2011 in a Case Study in Turkey

Tural D., Elicin O., BATUR Ş., Arslan D., ÖZ A. B., Serdengecti S., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.10, ss.6065-6068, 2013 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler 3

1. Neutrophil to lymphocyte ratio is an independent prognostic factor in patients with recurrent or metastatic head and neck squamous cell cancer.

Salim D. K., Mutlu H., Eryilmaz M. K., Salim O., Musri F. Y., Tural D., et al.

Molecular and clinical oncology , cilt.3, ss.839-842, 2015 (ESCI)

2. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors

KIVRAK SALİM D., MUTLU H., KARAKURT ERYILMAZ M., YALÇIN MÜSRİ F., TURAL D., GÜNDÜZ Ş., et al.

asian pac J cancer pre , cilt.18, sa.15, ss.7737-40, 2014 (Hakemli Dergi) Sürdürülebilir Kalkınma

3. Isolated uterine metastasis of invasive ductal carcinoma.

ASLAN D., TURAL D., TATLI A. M., AKAR E., UYSAL M., ERDOĞAN G.

Case Rep Oncol Med. , cilt.1, ss.1-3, 2013 (Hakemli Dergi)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 9

1. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience

Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)

2. CRIZOTINIB EFFICACY IN ALK-POSITIVE ADVANCEDSTAGE NON-SMALL CELL LUNG CANCER PATIENTS: A REAL-WORLD EXPERIENCE FROM TURKEY

KILIÇKAP S., ÖZTÜRK a., KARADURMUŞ N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., et al.

IASLC 2018, 23 - 26 Eylül 2018, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

290

H-İndeks (WoS)

Atıf (Scopus)

294

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler